

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <http://orca.cf.ac.uk/72118/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Cilibrasi, Vincenzo, Tsang, Kwok Ying Ingrid, Morelli, Matteo, Solfa, Francesca, Wiggins, Helen, Jones, Arwyn Tomos and Westwell, Andrew David 2015. Synthesis of substituted carbamo(dithioperoxo)thioates as potential BCA2-inhibitory anticancer agents. *Tetrahedron Letters* 56 (20) , pp. 2583-2585. 10.1016/j.tetlet.2015.03.132 file

Publishers page: <http://dx.doi.org/10.1016/j.tetlet.2015.03.132>
<<http://dx.doi.org/10.1016/j.tetlet.2015.03.132>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.




Graphical Abstract

To create your abstract, type over the instructions in the template box below.
Fonts or abstract dimensions should not be changed or altered.

Synthesis of substituted carbamo(dithioperoxo)thioates as potential BCA2-inhibitory anticancer agents

Vincenzo Cilibrasi, Kwok Tsang, Matteo Morelli, Francesca Solfa, Helen L. Wiggins, Arwyn T. Jones, Andrew D. Westwell



Leave this area blank for abstract info.



Synthesis of substituted carbamo(dithioperoxo)thioates as potential BCA2-inhibitory anticancer agents

Vincenzo Cilibrasi,^{a,b} Kwok Tsang,^a Matteo Morelli,^{a,c} Francesca Solfa,^a Helen L. Wiggins,^a Arwyn T. Jones,^a Andrew D. Westwell^{a*}

^aSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, Wales, U.K.

^bDipartimento di Scienze e Tecnologie Molecolari e Biomolecolari (STEMBIO), University of Palermo, Via Archirafi, 32-90123, Palermo, Italy

^cDipartimento di Farmacia, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy

ARTICLE INFO

Article history:

Received

Received in revised form

Accepted

Available online

Keywords:

Carbamo(dithioperoxo)thioates

Tetrabromomethane

Disulfiram analogues

BCA2 inhibitors

Anticancer agents

ABSTRACT

A new, simple, one-step synthetic route to carbamo(dithioperoxo)thioates from commercially available starting materials is described. The key step of this new synthetic approach involves the tetrabromomethane-promoted reaction between secondary amines, carbon disulfide and alkyl thiols under basic conditions at room temperature. New compounds from this series selected for anticancer screening showed selective sub-micromolar activity within BCA2-expressing human breast cancer cell lines.

2009 Elsevier Ltd. All rights reserved.

The thiram disulfide, disulfiram (Antabuse®, Figure 1) is a well-established drug used in the treatment of alcoholism (aversion therapy) by virtue of its aldehyde dehydrogenase (ALDH) inhibitory activity.¹ Previous studies within our group have identified disulfiram as a zinc-binding inhibitor of the E3 ubiquitin ligase enzyme, BCA2 (Breast Cancer Associated protein 2),² a clinically over-expressed protein in breast cancer patients and a target for cancer drug discovery.³ The interesting and multi-faceted anticancer activity of disulfiram, coupled with its favourable clinical toxicological and safety profile, has led to the initiation of several cancer clinical trials using this agent.⁴

Figure 1. Chemical structures of disulfiram and carbamo(dithioperoxo)thioates as potential metabolites.

The *in vivo* pharmacokinetic profile of disulfiram in patients is complex and is incompletely understood. The initial cleavage of the weak disulfide bond to form the corresponding diethyldithiocarbamate anion (known as ditiocarb) is well established. It has been postulated that the complex of ditiocarb with copper(II) ions (CuEt) formed in the blood is likely to be responsible for the anticancer activity of disulfiram.⁵ An alternative reported pharmacokinetic pathway involves the formation of carbamo(dithioperoxo)thioates (mixed disulfides derived from disulfiram, Figure 1) following initial formation of ditiocarb. Notably carbamo(dithioperoxo)thioates have been reported as inhibitors of human mitochondrial⁶ and sheep liver⁷

* Corresponding author. Tel.: +44 (0)2920875800. E-mail address: WestwellA@cf.ac.uk (A. Westwell).

ALDH, the therapeutic target on which clinical approval of disulfiram is based.

During previous work investigating the BCA2-inhibitory activity of disulfiram analogues, we synthesized a small series of carbamo(dithioperoxo)thioates by heating a mixture of disulfiram (or related piperidinyl or pyrrolidinyl analogues) with alkyl thiols in ethanol under reflux (Scheme 1).² This procedure led to the formation of the required carbamo(dithioperoxo)thioate products in low yields (9-25%) following extensive column chromatography, alongside a number of mixed disulfide-based by-products.

Scheme 1. Previously reported synthesis of carbamo(dithioperoxo)thioates by reaction of disulfiram analogues with alkyl thiols.

Testing of new disulfiram analogues and the structurally related carbamo(dithioperoxo)thioates in human breast cancer cell lines with differing levels of expression of BCA2, including isogenic cell lines MDA-MB-231 (BCA^{low/-}) and MDA-MB-231/ER (BCA²⁺), revealed interesting results.² Of particular note were the carbamo(dithioperoxo)thioates derived from reaction of disulfiram with hexanethiol or 2-mercaptoethanol (Figure 1; R = *n*-hexyl, HOCH₂CH₂). Both of these analogues exhibited sub-micromolar IC₅₀ activity selectively in BCA2-expressing breast cancer cell lines, whilst lacking the ALDH-inhibitory activity characteristic of the parent compound disulfiram.

Given the biological relevance of the carbamo(dithioperoxo)thioates in the context of anticancer drug discovery, and the difficulties in obtaining pure products through the previously described mixed disulfide method,² we required a new synthetic protocol for reliable and high yielding access to this class of compound. In this paper, we describe a simple, one-step protocol for the synthesis of a range of substituted carbamo(dithioperoxo)thioates under mild conditions. Our new method is based on the procedure developed by Liang and co-workers, using tetrabromomethane (CBr₄) to promote the synthesis of thioureas and thiuram disulfides via reaction of amines with carbon disulfide.⁸ The use of carbon tetrabromide to promote the reaction of dithioic acids or thiols with active methylene compounds to produce dithiocarbamates, xanthates, dithioesters and thioethers has also been previously reported.⁹ Critical to these studies was the proposed generation of a sulfenyl bromide intermediate.

We now report the extension of the above studies to the synthesis of carbamo(dithioperoxo)thioates. Initially, we optimized the reaction conditions based on the reaction between diethylamine, carbon disulfide, 2-mercaptoethanol or hexanethiol, and triethylamine as the base, to investigate the formation of the previously described lead compounds shown in Figure 1 (R = *n*-hexyl, HOCH₂CH₂). As a first adaptation of the previously reported method,⁸ the use of equimolar quantities of reagents without base in DMF as the solvent at room temperature gave very low yields of product. Reactions of equimolar quantities of these reagents promoted by triethylamine in dichloromethane in the absence of CBr₄ did not lead to the desired carbamo(dithioperoxo)thioate products. Adding one equivalent of CBr₄ in dichloromethane produced the products in 48% and 38% yields, respectively. Surprisingly, the use of two equivalents of alkyl thiol did not lead to the desired products, instead yielding the corresponding dithiocarbamates (confirmed by mass spectrometry and NMR) as by-products. Finally, it was found that the use of two equivalents of CBr₄ gave the products in good yields (85% and 58%, respectively) under mild conditions (room temperature, 2 h reaction time). This optimized procedure was subsequently adopted for the synthesis of new carbamo(dithioperoxo)thioate analogues.

Following mixing of equimolar quantities of secondary amine (**1a-f**) and alkyl thiol (**2a-d**) in anhydrous dichloromethane, the mixture was cooled in an ice bath. Carbon disulfide (1 equiv) was then added dropwise, followed by slow addition of triethylamine (1.1 equiv). After a further five minutes, a solution of CBr₄ (2 equiv) in dichloromethane was added, followed by stirring at room temperature for two hours. Product work-up and purification by column chromatography gave carbamo(dithioperoxo)thioates **3a-x** (>60% yield in most cases) (Scheme 2).

Scheme 2. Optimized synthesis of carbamo(dithioperoxo)thioate analogues **3a-x**.

The identity of the carbamo(dithioperoxo)thioate products was confirmed by NMR spectroscopy and mass spectrometry. Compound purity following column chromatography was further verified by either microanalysis (duplicate % CHN) or accurate mass determination (see Supplementary data). Good yields were obtained for the majority of products, however, in the case of compounds **3q** and **3u** (derived from 2-mercaptoethanol and

morpholine or *N*-methylpiperazine), lower yields (25% and 30% respectively) were obtained. Overall, our results are consistent with the formation of an intermediate sulfenyl bromide, as was postulated in the previous related studies.^{8,9}

As a continuation of our previously published studies on the anticancer properties of these new disulfiram-derived molecules,^{1,2} we carried out a preliminary *in vitro* evaluation across human breast cancer cell lines where BCA2 expression status was known (72 h compound treatment time). The mean IC₅₀ values (triplicate analysis) for compounds **3i**, **3k**, **3o**, **3s** and **3w** (derived from a variety of secondary amines) in human breast cancer cell lines MCF-7 (BCA2-positive), MDA-MB-231 (BCA2-negative) and MCF-10A (non-cancerous control) were determined. The results presented in Table 1 indicate selective sub-micromolar IC₅₀ activity selectively within MCF-7 cells, consistent with previously synthesized analogues of this broad class.² One analogue (**3o**) possessed a biphasic dose-response profile, a phenomenon previously observed within our group for disulfiram.¹

In conclusion, we have developed and optimized a new one-pot synthetic route to a range of potential anticancer carbamo(dithioperoxo)thioates in high yields, including the previous BCA2-inhibitory compounds from our previous study (compounds **3a** and **3c** in 58% and 85% yields, respectively). Further studies of the anticancer properties of this new series are ongoing.

Acknowledgments

The authors acknowledge the support of Cardiff University, the University of Palermo (Italy, to V.C.), and the University of Pisa (Italy, to M.M.) for financial support. We thank Cancer Research Wales for PhD studentship support (to H.L.W.), and the EPSRC National Mass Spectrometry Facility (Swansea) for provision of accurate mass spectrometric analysis.

Supplementary Data

Supplementary data (experimental procedures and characterization data, including NMR and mass spectrometry data for all isolated compounds, and the *in vitro* testing protocol) associated with this article can be found in the online version.

References

- Wiggins, H. L.; Wymant, J. M.; Solfa, F.; Hiscox, S. E.; Taylor, K. M.; Westwell, A. D.; Jones, A. T. *Biochem. Pharmacol.* **2015**, *93*, 332-342.
- Brahemi, G.; Kona, F. R.; Fiasella, A.; Buac, D.; Soukupová, J.; Brancale, A.; Burger, A. M.; Westwell, A. D. *J. Med. Chem.* **2010**, *53*, 2757-2765.
- Burger, A. M.; Gao, Y.; Amemiya, Y.; Kahn, H. J.; Kitching, R.; Yang, Y.; Sun, P.; Narod, S. A.; Hanna, W. M.; Seth, A. K. *Cancer Res.* **2005**, *65*, 10401-10412.
- Cvek, B. *Drug Discov. Today* **2012**, *17*, 409-412.
- Cvek, B. *Curr. Cancer Drug Targets* **2011**, *11*, 332-337.
- Mackerell, A. D.; Vallari, R. C.; Pietruszko, R. *FEBS Lett.* **1985**, *179*, 77-81.
- Kitson, T. M.; *Biochem. J.* **1975**, *151*, 407-412.
- Liang, F.; Tan, J.; Piao, C.; Liu, Q. *Synthesis* **2008**, 3579-3584.
- Tan, J.; Liang, F.; Wang, Y.; Cheng, X.; Liu, Q.; Yuan, H. *Org. Lett.* **2008**, *10*, 2485-2488.

Compound	MCF-7	MDA-MB-231	MCF-10A
3i	0.5	>10	>10
3k	0.9	>10	>10
3o	0.6 ^a	>10	>10
3s	1	10	>10
3w	0.9	>10	>10

The results are the mean values from three independent experiments;

^a indicates the first IC₅₀ value of a biphasic dose-response profile.

Table 1. IC₅₀ values (μM) in human breast cancer cell lines MCF-7 (BCA2 +ve), MDA-MB-231 (BCA2 -ve) and MCF-10A (control proliferative cell line).






Figure 1. Chemical structures of disulfiram and carbamo(dithioperoxo)thioates as potential metabolites.



Scheme 1. Previously reported synthesis of carbamo(dithioperoxo)thioates by reaction of disulfiram analogues with alkyl thiols.



	R	R ¹	Yield		R	R ¹	Yield		R	R ¹	Yield
3a	Et	CH ₂ CH ₂ OH	58	3i	-(CH ₂) ₄ -	CH ₂ CH ₂ OH	60	3q	-(CH ₂) ₂ O(CH ₂) ₂ -	CH ₂ CH ₂ OH	25
3b	Et	<i>i</i> -Pr	78	3j	-(CH ₂) ₄ -	<i>i</i> -Pr	90	3r	-(CH ₂) ₂ O(CH ₂) ₂ -	<i>i</i> -Pr	75
3c	Et	<i>n</i> -Hex	85	3k	-(CH ₂) ₄ -	<i>n</i> -Hex	85	3s	-(CH ₂) ₂ O(CH ₂) ₂ -	<i>n</i> -Hex	85
3d	Et	Cyclohexyl	68	3l	-(CH ₂) ₄ -	Cyclohexyl	95	3t	-(CH ₂) ₂ O(CH ₂) ₂ -	Cyclohexyl	90
3e	Bu	CH ₂ CH ₂ OH	64	3m	-(CH ₂) ₅ -	CH ₂ CH ₂ OH	65	3u	-(CH ₂) ₂ NMe(CH ₂) ₂ -	CH ₂ CH ₂ OH	30
3f	Bu	<i>i</i> -Pr	68	3n	-(CH ₂) ₅ -	<i>i</i> -Pr	68	3v	-(CH ₂) ₂ NMe(CH ₂) ₂ -	<i>i</i> -Pr	76
3g	Bu	<i>n</i> -Hex	80	3o	-(CH ₂) ₅ -	<i>n</i> -Hex	80	3w	-(CH ₂) ₂ NMe(CH ₂) ₂ -	<i>n</i> -Hex	70
3h	Bu	Cyclohexyl	80	3p	-(CH ₂) ₅ -	Cyclohexyl	90	3x	-(CH ₂) ₂ NMe(CH ₂) ₂ -	Cyclohexyl	75

Scheme 2. Optimized synthesis of carbamo(dithioperoxo)thioate analogues **3a-x**.